IL312675A - Conjugates involving phosphorus (V) and a drug component - Google Patents

Conjugates involving phosphorus (V) and a drug component

Info

Publication number
IL312675A
IL312675A IL312675A IL31267524A IL312675A IL 312675 A IL312675 A IL 312675A IL 312675 A IL312675 A IL 312675A IL 31267524 A IL31267524 A IL 31267524A IL 312675 A IL312675 A IL 312675A
Authority
IL
Israel
Prior art keywords
conjugates
phosphorus
drug moiety
moiety
drug
Prior art date
Application number
IL312675A
Other languages
English (en)
Hebrew (he)
Inventor
Jonas Helma-Smets
Jahaziel Jahzerah
Marc-Andr? KASPER
Paul Machui
Isabelle Mai
Philipp Ochtrop
Dominik Schumacher
Christian Hackenberger
Original Assignee
Tubulis Gmbh
Forschungsverbund Berlin Ev
Helma Smets Jonas
Jahaziel Jahzerah
Kasper Marc Andr?
Paul Machui
Isabelle Mai
Philipp Ochtrop
Dominik Schumacher
Christian Hackenberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tubulis Gmbh, Forschungsverbund Berlin Ev, Helma Smets Jonas, Jahaziel Jahzerah, Kasper Marc Andr?, Paul Machui, Isabelle Mai, Philipp Ochtrop, Dominik Schumacher, Christian Hackenberger filed Critical Tubulis Gmbh
Publication of IL312675A publication Critical patent/IL312675A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL312675A 2021-11-09 2022-11-09 Conjugates involving phosphorus (V) and a drug component IL312675A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207195 2021-11-09
PCT/EP2022/081345 WO2023083900A1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety

Publications (1)

Publication Number Publication Date
IL312675A true IL312675A (en) 2024-07-01

Family

ID=78592631

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312675A IL312675A (en) 2021-11-09 2022-11-09 Conjugates involving phosphorus (V) and a drug component

Country Status (15)

Country Link
US (2) US20230330258A1 (enExample)
EP (1) EP4429708A1 (enExample)
JP (1) JP2024540691A (enExample)
KR (1) KR20240100413A (enExample)
CN (1) CN118302197A (enExample)
AU (1) AU2022385379A1 (enExample)
CA (1) CA3237371A1 (enExample)
CL (1) CL2024001372A1 (enExample)
CO (1) CO2024005877A2 (enExample)
DE (1) DE22817174T1 (enExample)
ES (1) ES2999335T1 (enExample)
IL (1) IL312675A (enExample)
MX (1) MX2024005546A (enExample)
PE (1) PE20242107A1 (enExample)
WO (1) WO2023083900A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4637832A1 (en) * 2022-12-22 2025-10-29 Tubulis GmbH Conjugates comprising a phosphorus(v) moiety and a drug
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
AU2024332412A1 (en) 2023-09-01 2026-03-12 Tubulis Gmbh Methods of preparing phosphonamidate compounds
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
AU2017320913B2 (en) 2016-09-01 2024-08-15 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
KR102772724B1 (ko) 2018-03-07 2025-02-24 포슝스베르분드 베를린 에.베. 알켄 또는 알킨-포스포노티올레이트 및 -포스포네이트로의 화학선택적 티올-접합
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物

Also Published As

Publication number Publication date
WO2023083900A1 (en) 2023-05-19
US20230330258A1 (en) 2023-10-19
CL2024001372A1 (es) 2024-10-25
KR20240100413A (ko) 2024-07-01
ES2999335T1 (en) 2025-02-25
DE22817174T1 (de) 2024-12-12
CN118302197A (zh) 2024-07-05
CA3237371A1 (en) 2023-05-19
JP2024540691A (ja) 2024-10-31
US20250281634A1 (en) 2025-09-11
MX2024005546A (es) 2024-07-10
EP4429708A1 (en) 2024-09-18
CO2024005877A2 (es) 2024-07-08
PE20242107A1 (es) 2024-10-28
AU2022385379A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
IL312675A (en) Conjugates involving phosphorus (V) and a drug component
IL312677A (en) Conjugates including phosphorus (V) and a camptothecin component
IL315508A (en) Camptothecin conjugates
IL313805A (en) Drug antibody conjugates
IL188999A0 (en) Conjugates of a g-csf moiety and a polymer
IL325445A (en) Camptothecin drug and its antibody conjugate
IL318829A (en) Cytotoxic compounds and their conjugates
IL309360A (en) drug peptide conjugates
EP4237040A4 (en) PATCH-TYPE DRUG INFUSION DEVICE
IL317447A (en) Antibody-drug conjugates
ZA202211123B (en) Drug antibody conjugates
EP4192840A4 (en) MACROPHAGE TARGETED DRUG CONJUGATES
HUE072483T2 (hu) Elektromos cigaretta
HK40110555A (en) Conjugates comprising a phosphorus (v) and a drug moiety
HK40127624A (en) Conjugates comprising a phosphorus(v) moiety and a drug
CA3277761A1 (en) Conjugates comprising a phosphorus(v) moiety and a drug
IL326503A (en) Bracelets that include split links
HK40111039A (en) Conjugates comprising a phosphorus (v) and a camptothecin moiety
CA3288936A1 (en) Ligand-polar drug conjugates
HK40101817A (en) Arrangement for a drug delivery device and drug delivery device
HK40096945A (en) Arrangement for a drug delivery device and drug delivery device
HK40100789A (en) Arrangement for a drug delivery device and drug delivery device
HK40110422A (en) Peptide drug conjugates
GB202508100D0 (en) Novel compounds and drug conjugates
GB202508102D0 (en) Novel compounds and drug conjugates